Xilio inks Merck deal to run checkpoint inhibitor combo trial

Xilio Therapeutics has struck a deal with Merck to test its anti-CTLA-4 monoclonal antibody XTX101 in combination with Keytruda. The agreement sets Xilio up to show whether it can combine the checkpoint inhibitors without causing the toxicities associated with other cocktails that target CTLA-4 and PD-1.